Pancreas Cancer
Conditions
Keywords
Pancreas Cancer
Brief summary
The goal of this research is to study an intervention, which the investigators call Supportive Oncology Care at Home, that entails both remote patient monitoring (e.g. patient-reported symptoms, home monitored vital signs, and body weight) and a Medically Home care model (e.g. triggers for phone calls and visits to patients' homes to address and manage any concerning issues identified). Specifically, the investigators will conduct a single arm pilot study (N=20) in patients with pancreatic cancer who sign consent for parent trial of neoadjuvant FOLFIRINOX (18-179) receiving preoperative FOLFIRINOX to assess the feasibility and acceptability of Supportive Oncology Care at Home.
Detailed description
Preoperative treatment can cause significant morbidity and often result in hospitalizations. Patients receiving preoperative FOLFIRINOX often experience numerous side effects, including nausea, vomiting, diarrhea, fatigue, fever, neuropathy, and loss of appetite. Frequently, patients require hospital admissions to help address uncontrolled symptoms related to their cancer and side effects related to the treatment, Interventions targeting patients' symptoms and delivering care to patients at their homes have the potential to improve patient outcomes. Studies show that interventions targeting patients' symptoms can improve symptom management, enhance quality of life (QOL), and prevent hospitalizations. Medically Home interventions have shown the potential to enhance patient outcomes. The Medically Home model of care is an alternative to a hospital admission for acute care and treatment of a clinical condition. Medically Home interventions entail providing medical care to acutely ill patients in their home. In addition, research in the general medicine literature has demonstrated that interventions involving remote patient monitoring with 'triggers' for visits to patients' homes for worrisome symptoms can enhance care outcomes. Although this research demonstrates promising results, these studies have not been conducted among patients with cancer. Notably, the prior work involving home monitoring with visits as needed has lacked patient-reported outcomes, such as symptom monitoring. Thus, efforts are needed to develop and test interventions containing both symptom monitoring and the potential for home visits when necessary in a population of patients with cancer.
Interventions
Entails the following: 1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm; 2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy; 3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
Sponsors
Stand Up To Cancer
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 or older * Within three weeks of signing consent for parent trial of neoadjuvant FOLFIRINOX * Planning to receive care at Massachusetts General Hospital * Ability to read and respond to questions in English * Residing within 50 miles of Massachusetts General Hospital
Exclusion criteria
-Uncontrolled psychiatric illness or impaired cognition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rates of study enrollment | 2 years | Proportion of patients who agree to participate in the study and sign informed consent. |
| Rates of completion | 2 years | Proportion of patients who complete daily patient-reported symptom assessments within the first two weeks of enrollment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative dose of FOLFIRINOX received | 2 years | Describe the cumulative dose of FOLFIRINOX received |
| Rates of completion of daily symptom monitoring | 2 years | Proportion of participants completing daily symptom monitoring throughout the study |
| Rates of completion of weekly body weight | 2 years | Proportion of participants completing weekly reporting of body weight throughout the study |
| Number of home visits required | 2 years | Number of home visits required, their average duration, the issues addressed at home, and the interventions delivered to patients at their home |
| Number of phone calls required | 2 years | Number of phone calls required per patient as well as average duration of these calls |
| Number of emails required | 2 years | Number of emails from Medically Home to the primary oncology team |
| Patient acceptability | 2 years | Qualitative acceptability ratings from patients regarding helpfulness, convenience, and perceptions of the study. |
| Family caregiver acceptability | 2 years | Qualitative acceptability ratings from family caregivers regarding helpfulness, convenience, and perceptions of the study. |
| Clinician acceptability | 2 years | Qualitative acceptability ratings from clinicians regarding helpfulness, convenience, and perceptions of the study. |
| Number of emergency department visits | 2 Years | The number of emergency department \[ED\] visits and the proportion of patients needing an emergency department \[ED\] visit |
| Number of urgent visits | 2 Years | The number of urgent visits to clinic and the proportion of patients needing an urgent visit to clinic |
| Number of hospital admissions | 2 Years | The number of hospital admissions and the proportion of patients needing a hospital admission |
| Change in symptom burden longitudinally throughout the study | 2 years | Change in symptom burden (assessed using Edmonton Symptom Assessment System-revised \[ESAS-r\], range 0-10 for each symptom with higher scores indicating worse symptom burden) throughout the study. |
| Change in psychological distress | 2 years | Change in psychological distress (assessed using the Patient Health Questionnaire-4 \[PHQ-4\], range 0-12 with higher scores indicating greater distress, and subscales for depression/anxiety ranging 0-6 with higher scores indicating greater distress) throughout the study. |
| Change in quality of life longitudinally throughout the study | 2 Years | Change in quality of life (assessed using the Functional Assessment of Cancer Therapy-General \[FACT-G\], with range of 0-108 and higher scores indicating better quality of life) throughout the study. |
| Number of cycles of FOLFIRINOX received | 2 years | Describe the number of cycles of FOLFIRINOX chemotherapy received by patients |
| Number of treatment delays | 2 years | Describe the number of treatment delays for patients |
| Rates of completion of daily vital signs | 2 years | Proportion of participants completing daily reporting of vital signs throughout the study |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of hospital admissions | 2 years | Compare difference in number of hospital admissions between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Proportion of patients requiring an emergency department visit | 2 years | Compare difference in proportion of patients with emergency department visits between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Number of emergency department visits | 2 years | Compare difference in number of emergency department visits between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Proportion of patients requiring an urgent care visit | 2 years | Compare difference in proportion of patients with urgent care visits between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Number of urgent care visits | 2 years | Compare difference in number of urgent care visits between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Proportion of patients requiring a hospital admission or emergency department visit | 2 years | Compare difference in proportion of patients with a hospital admission or emergency department visit between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Number of hospital admissions or emergency department visits | 2 years | Compare difference in number of hospital admissions or emergency department visits between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Proportion of patients requiring a treatment delay | 2 years | Compare difference in proportion of patients with a treatment delay between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Proportion of days in hospital or emergency department | 2 years | Compare difference in proportion of days in hospital or emergency department between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Proportion of days in hospital, emergency department, or urgent care | 2 years | Compare difference in proportion of days in hospital, emergency department, or urgent care between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Number of cycles of chemotherapy completed | 2 years | Compare difference in number of cycles of chemotherapy completed between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Numbers of treatment delays | 2 years | Compare difference in number of treatment delays between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Dose intensity | 2 years | Compare difference in chemotherapy dose intensity between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Overall survival | 2 years | Compare difference in overall survival between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Progression free survival | 2 years | Compare difference in progression free survival between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
| Proportion of patients requiring a hospital admission | 2 years | Compare difference in proportion of patients with hospital admissions between patients with pancreatic cancer receiving preoperative FOLFIRINOX who did and did not receive Supportive Oncology Care at Home |
Countries
United States
Outcome results
None listed